Abzena: Abzena Supplies Clinical Trial Material for Angiex's Phase I Study of AGX101, a First-in-Class TM4SF1-directed ADC
SAN DIEGO, Aug. 8, 2024 /PRNewswire/ -- Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for their Pha...
Read full article »
Abzena is an England-based contract research organization that offers services such as antibody discovery and drug conjugate development for the biopharmaceutical sector.
Read more